Video

Blake A. Morrison Discusses the Excitement in Myeloma Research

Author(s):

Blake A. Morrison

Blake A. Morrison discusses the recent excitement in myeloma research.

Blake A. Morrison, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses the recent excitement in myeloma research.

Morrison touches on the approvals of Empliciti (elotuzumab), Ninlaro (ixazomib) and Darzalex (daratumumab), as well as the research into CAR T cell immunotherapy.

Read more of our coverage from the 2015 ASH Annual Meeting

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.
Related Content
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Dr. Surbhi Sidana discussed the topic of minimal residual disease: nobeastsofierce - stock.adobe.com
April 1st 2025

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

Alex Biese
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
Illustration of cells.
March 27th 2025

Quadruplet Regimen Preferable to Triplets in Multiple Myeloma

Alex Biese
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.